T2 Biosystems Stock Price, News & Analysis

T2 Biosystems, Inc. (NASDAQ:TTOO) presented new clinical data at the ECCMID conference, reinforcing the effectiveness of its T2Bacteria® and T2Candida® Panels. These sepsis panels, utilized with the T2Dx® Instrument, demonstrate rapid and accurate detection of pathogens, crucial for improving patient outcomes in critical care settings.

The T2Bacteria Panel effectively detected 77% of bloodstream infections and led to a 50% change in antibiotic therapy at Motol University Hospital. The T2 sepsis panels have gained routine clinical usage at Karolinska University Hospital due to their high specificity and sensitivity. The T2MR technology significantly reduces the time for targeted therapy, allowing decisions up to 35 hours earlier than traditional blood cultures.

T2 Biosystems (NASDAQ:TTOO) announced the launch of a new webinar and white paper on the T2Candida Panel, focusing on its clinical data and real-world applications in Medical Intensive Care Units (MICU). The T2Candida Panel enables rapid detection of sepsis-causing fungal pathogens directly from whole blood, significantly shortening the time to diagnosis and antifungal treatment while reducing therapy duration. Dr. Neil Clancy emphasized its importance for critically ill patients. The white paper includes user experiences, treatment algorithms, and patient outcomes, underscoring the panel's role in improving patient care amidst increasing candidiasis risks in immunocompromised patients.

T2 Biosystems (NASDAQ:TTOO) announced plans to enhance its FDA-cleared T2Candida Panel by adding the detection of the multidrug-resistant fungal pathogen Candida auris. This pathogen poses a significant threat, with a mortality rate of up to 60%, especially among vulnerable populations. The CDC highlights the challenge of identifying Candida auris using conventional lab methods, which can hinder effective treatment. T2's innovative test aims to provide faster detection directly from blood samples, potentially improving patient outcomes. The company is also pursuing partnerships to expedite commercialization of this test.

T2 Biosystems, Inc. (NASDAQ:TTOO) reported a total revenue of $22.3 million for 2022, with $11.3 million from product sales and $11.0 million from research contributions. The company achieved record sepsis product revenue of $8.4 million in 2022, a 17% increase from 2021. However, total revenue for Q4 2022 decreased by 21% year-over-year to $5.5 million, with product revenue down 45%. The net loss for the year was $62.3 million, or $12.28 per share. Looking forward, T2 expects 2023 sepsis product revenue between $11.0 million and $13.0 million, a projected growth of 31% to 55%.